DN-022150

Primary objective: Evaluate the safety and tolerability of DN022150 for injection in subjects with advanced solid tumors carrying KRAS G12D mutations; explore the maximum tolerated dose (MTD) of DN022150 for injection and determine the recommended dose (RP2D) for phase II clinical studies. Evaluate the efficacy of DN022150 for injection in subjects with advanced solid tumors carrying KRAS G12D mutations. Secondary objective: Evaluate the pharmacokinetic (PK) characteristics of DN022150 for injection in subjects with advanced solid tumors carrying KRAS G12D mutations. Exploratory objective: Explore the correlation between the mutation frequency (VAF) of KRAS G12D and clinical efficacy; Evaluate the effect of DN022150 for injection on the QT/QTc interval of subjects with advanced solid tumors carrying KRAS G12D mutations; Explore the relationship between co-mutated genes and clinical efficacy and the mechanism of drug resistance. Explore the drug exposure-effect relationship.